Tourette’s Syndrome – Society of Cannabis Clinicians https://www.cannabisclinicians.org Educating Healthcare Professionals about the Medical Use of Cannabis Sun, 11 Jun 2023 11:30:24 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.3 https://www.cannabisclinicians.org/wp-content/uploads/2020/07/cropped-scc-flavicon-32x32.png Tourette’s Syndrome – Society of Cannabis Clinicians https://www.cannabisclinicians.org 32 32 Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome https://www.cannabisclinicians.org/2023/06/11/tetrahydrocannabinol-and-cannabidiol-in-tourette-syndrome/ Sun, 11 Jun 2023 11:30:24 +0000 https://www.cannabisclinicians.org/?p=28773 Tourette syndrome is characterized by chronic motor and vocal tics. There is preliminary evidence of benefit from cannabis products containing D9-tetrahydrocannabi- nol (THC) and that coadministration of cannabidiol (CBD) improves the side-effect profile and safety.In this double-blind, crossover trial, participants with severe Tourette syndrome were randomly assigned to a 6-week treatment period with escalating doses of an oral oil containing 5 mg/ml of THC and 5 mg/ml of CBD, followed by a 6-week course of placebo, or vice versa, separated by a 4-week washout period. The primary outcome was the total tic score on the Yale Global Tic Severity Scale (YGTSS; range, 0 to 50 [higher scores indicate greater severity of symptoms]). Secondary outcomes included video-based assessment of tics, global impairment, anxiety, depression, and obsessive-compulsive symptoms. Out- comes were correlated with plasma levels of cannabinoid metabolites. A computerized cogni- tive battery was administered at the beginning and the end of each treatment period.

The post Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome appeared first on Society of Cannabis Clinicians.

]]> Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review https://www.cannabisclinicians.org/2023/04/29/efficacy-of-cannabinoids-in-neurodevelopmental-and-neuropsychiatric-disorders-among-children-and-adolescents-a-systematic-review-2/ Sat, 29 Apr 2023 11:56:31 +0000 https://www.cannabisclinicians.org/?p=28481 A better understanding of the endocannabinoid system and a relaxation in regulatory control of cannabis globally has increased interest in the medicinal use of cannabinoid-based products (CBP). We provide a systematic review of the rationale and current clinical trial evidence for CBP in the treatment of neuropsychiatric and neurodevelopmental disorders in children and adolescents. A systematic search of MEDLINE, Embase, PsycINFO, and the Cochrane Central Register of Trials was performed to identify articles published after 1980 about CBP for medical purposes in individuals aged 18 years or younger with selected neuropsychiatric or neurodevelopmental conditions. Risk of bias and quality of evidence was assessed for each article. Of 4466 articles screened, 18 were eligible for inclusion, addressing eight conditions (anxiety disorders (n = 1); autism spectrum disorder (n = 5); foetal alcohol spectrum disorder (n = 1); fragile X syndrome (n = 2); intellectual disability (n = 1); mood disorders (n = 2); post-traumatic stress disorder (n = 3); and Tourette syndrome (n = 3)). Only one randomised controlled trial (RCT) was identified. The remaining seventeen articles included one open-label trial, three uncontrolled before-and-after trials, two case series and 11 case reports, thus the risk of bias was high. Despite growing community and scientific interest, our systematic review identified limited and generally poor-quality evidence for the efficacy of CBP in neuropsychiatric and neurodevelopmental disorders in children and adolescents. Large rigorous RCTs are required to inform clinical care. In the meantime, clinicians must balance patient expectations with the limited evidence available.

The post Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review appeared first on Society of Cannabis Clinicians.

]]> The therapeutic role of Cannabidiol in mental health: a systematic review https://www.cannabisclinicians.org/2022/03/14/the-therapeutic-role-of-cannabidiol-in-mental-health-a-systematic-review/ Mon, 14 Mar 2022 22:50:22 +0000 https://www.cannabisclinicians.org/?p=26278 The therapeutic application of cannabidiol (CBD) is gaining interest due to expanding evidence for its use.
Objective: To summarize the clinical outcomes, study designs and limitations for the use of CBD and nabiximols (whole plant extract from Cannabis sativa L. that has been purified into 1:1 ratio of CBD and delta-9- tetrahydrocannabinol) in the treatment of psychiatric disorders.

The post The therapeutic role of Cannabidiol in mental health: a systematic review appeared first on Society of Cannabis Clinicians.

]]> Cannabis Therapeutics and the Future of Neurology https://www.cannabisclinicians.org/2020/08/17/cannabis-therapeutics-and-the-future-of-neurology/ Mon, 17 Aug 2020 15:56:53 +0000 https://www.cannabisclinicians.org/?p=19234 Author: Ethan B. Russo Published in: Frontiers in Integrative Neuroscience  October 2018 Abstract Introduction: Cannabis burst across the Western medicine horizon after its introduction by William O’Shaughnessy in 1838 (O’Shaughnessy, 1838–1840;...

The post Cannabis Therapeutics and the Future of Neurology appeared first on Society of Cannabis Clinicians.

]]> Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. https://www.cannabisclinicians.org/2015/06/23/cannabinoids-for-medical-use-a-systematic-review-and-meta-analysis/ Tue, 23 Jun 2015 16:09:53 +0000 http://cannabisclinicians.org/?p=10325 Authors: Penny F. Whiting, Robert F. Wolff, Sohan Deshpande, Marcello Di Nisio, Steven Duffy, et al
JAMA, 23 June 2015
---
IMPORTANCE: Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. OBJECTIVE: To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. DATA SOURCES: Twenty...

The post Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. appeared first on Society of Cannabis Clinicians.

]]> Association between pre- and perinatal exposures and Tourette syndrome or chronic tic disorder in the ALSPAC cohort. https://www.cannabisclinicians.org/2014/01/01/association-between-pre-and-perinatal-exposures-and-tourette-syndrome-or-chronic-tic-disorder-in-the-alspac-cohort/ Wed, 01 Jan 2014 14:59:32 +0000 https://www.cannabisclinicians.org/?p=15509 Authors: Carol A. Mathews, Jeremiah M. Scharf, Laura L. Miller, Corrie Macdonald-Wallis, et al
British Journal of Psychiatry, January 2014
---
BACKGROUND: Tourette syndrome and chronic tic disorder are heritable but aetiologically complex. Although environment plays a role in their development, existing studies of non-genetic risk factors are inconsistent. AIMS:
To examine the association between pre- and perinatal e...

The post Association between pre- and perinatal exposures and Tourette syndrome or chronic tic disorder in the ALSPAC cohort. appeared first on Society of Cannabis Clinicians.

]]> Cannabinoids for Tourette’s Syndrome. https://www.cannabisclinicians.org/2009/10/07/cannabinoids-for-tourettes-syndrome/ Wed, 07 Oct 2009 17:41:03 +0000 https://www.cannabisclinicians.org/?p=15352 Authors: Adrienne Curtis, Carl E Clarke, Hugh E Rickards
Cochrane Database of Systematic Reviews, 7 October 2009
---
BACKGROUND: Gilles de la Tourette Syndrome (GTS) is a developmental neuropsychiatric disorder characterised by the presence of chronic motor and phonic tics. Drugs currently used in the treatment of GTS either lack efficacy or are associated with intolerable side effects. Ther...

The post Cannabinoids for Tourette’s Syndrome. appeared first on Society of Cannabis Clinicians.

]]> Cannabinoids reduce symptoms of Tourette’s syndrome. https://www.cannabisclinicians.org/2003/10/01/cannabinoids-reduce-symptoms-of-tourettes-syndrome/ Wed, 01 Oct 2003 17:44:33 +0000 https://www.cannabisclinicians.org/?p=15354 Authors: Kirsten R Müller-Vahl
Expert Opinion on Pharmacotherapy, October 2003
---
Currently, the treatment of Tourette's syndrome (TS) is unsatisfactory. Therefore, there is expanding interest in new therapeutical strategies. Anecdotal reports suggested that the use of cannabis might improve not only tics, but also behavioural problems in patients with TS...

The post Cannabinoids reduce symptoms of Tourette’s syndrome. appeared first on Society of Cannabis Clinicians.

]]> Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. https://www.cannabisclinicians.org/2003/02/01/treatment-of-tourette-syndrome-with-delta-9-tetrahydrocannabinol-delta-9-thc-no-influence-on-neuropsychological-performance/ Sat, 01 Feb 2003 18:51:54 +0000 https://www.cannabisclinicians.org/?p=15356 Authors: Kirsten R Müller-Vahl, Heidrun Prevedel, Karen Theloe, Hans Kolbe, et al
Neuropsychopharmacology, February 2003
---
Previous studies provide evidence that marijuana (Cannabis sativa) and delta-9-tetrahydrocannabinol (Delta(9)-THC), the major psychoactive ingredient of marijuana, respectively, are effective in the treatment of tics and behavioral problems in Tourette syndrome (TS). It, there...

The post Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. appeared first on Society of Cannabis Clinicians.

]]>